Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - Results from The Clopidogrel for the Reduction of Events During Observation (CREDO) trial Article

Beinart, SC, Kolm, P, Veledar, E et al. (2005). Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention - Results from The Clopidogrel for the Reduction of Events During Observation (CREDO) trial . JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 46(5), 761-769. 10.1016/j.jacc.2005.03.073

Open Access Industry Collaboration International Collaboration

cited authors

  • Beinart, SC; Kolm, P; Veledar, E; Zhang, ZF; Mahoney, EM; Bouin, O; Gabriel, S; Jackson, J; Chen, R; Caro, J; Steinhubl, S; Topol, E; Weintraub, WS

sustainable development goals

authors

publication date

  • September 6, 2005

webpage

published in

keywords

  • ANTICOAGULATION
  • ASPIRIN
  • Cardiac & Cardiovascular Systems
  • Cardiovascular System & Cardiology
  • Life Sciences & Biomedicine
  • RISK
  • STRATEGY
  • SURVIVAL CURVES
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • ELSEVIER SCIENCE INC

start page

  • 761

end page

  • 769

volume

  • 46

issue

  • 5